| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis, Inclusion Body | 34 | 2023 | 145 | 6.170 |
Why?
|
| Muscular Diseases | 23 | 2024 | 553 | 5.240 |
Why?
|
| Myositis | 30 | 2024 | 271 | 4.820 |
Why?
|
| Dermatomyositis | 28 | 2023 | 258 | 4.210 |
Why?
|
| Peripheral Nervous System Diseases | 17 | 2023 | 710 | 2.930 |
Why?
|
| Guillain-Barre Syndrome | 10 | 2023 | 127 | 2.390 |
Why?
|
| Neuromuscular Diseases | 10 | 2021 | 258 | 2.240 |
Why?
|
| Polymyositis | 18 | 2023 | 75 | 2.220 |
Why?
|
| Myasthenia Gravis | 12 | 2022 | 214 | 2.050 |
Why?
|
| Muscle, Skeletal | 52 | 2022 | 4948 | 1.900 |
Why?
|
| Muscle Weakness | 15 | 2019 | 412 | 1.780 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 7 | 2022 | 62 | 1.780 |
Why?
|
| Muscular Dystrophies | 16 | 2014 | 390 | 1.690 |
Why?
|
| Electrodiagnosis | 9 | 2019 | 148 | 1.410 |
Why?
|
| Immunoglobulins, Intravenous | 14 | 2024 | 664 | 1.270 |
Why?
|
| Polyneuropathies | 8 | 2019 | 137 | 1.120 |
Why?
|
| Muscle Proteins | 11 | 2012 | 1154 | 1.020 |
Why?
|
| Myotonic Dystrophy | 4 | 2023 | 78 | 0.960 |
Why?
|
| cis-trans-Isomerases | 1 | 2024 | 44 | 0.950 |
Why?
|
| Retinal Dystrophies | 1 | 2024 | 65 | 0.900 |
Why?
|
| Fasciitis | 2 | 2016 | 67 | 0.890 |
Why?
|
| Immunologic Factors | 5 | 2021 | 1589 | 0.860 |
Why?
|
| Electroretinography | 1 | 2024 | 525 | 0.810 |
Why?
|
| Glycogen Storage Disease Type II | 4 | 2016 | 43 | 0.810 |
Why?
|
| Immunosuppressive Agents | 18 | 2020 | 4174 | 0.770 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 4 | 2013 | 34 | 0.760 |
Why?
|
| Scapula | 2 | 2013 | 173 | 0.750 |
Why?
|
| Neurology | 4 | 2020 | 780 | 0.730 |
Why?
|
| Biopsy | 31 | 2023 | 6766 | 0.730 |
Why?
|
| Leg | 5 | 2020 | 1088 | 0.720 |
Why?
|
| Neural Conduction | 14 | 2015 | 441 | 0.710 |
Why?
|
| Fibric Acids | 1 | 2019 | 27 | 0.690 |
Why?
|
| Multiple Acyl Coenzyme A Dehydrogenase Deficiency | 1 | 2019 | 6 | 0.660 |
Why?
|
| Tubulin Modulators | 1 | 2019 | 107 | 0.650 |
Why?
|
| Autoimmune Diseases | 5 | 2024 | 2244 | 0.630 |
Why?
|
| Charcot-Marie-Tooth Disease | 3 | 2021 | 100 | 0.630 |
Why?
|
| Interferon Type I | 5 | 2020 | 562 | 0.620 |
Why?
|
| Prednisone | 10 | 2021 | 1563 | 0.600 |
Why?
|
| Humans | 253 | 2024 | 761504 | 0.590 |
Why?
|
| Edema | 3 | 2020 | 766 | 0.590 |
Why?
|
| Amyloidosis | 2 | 2020 | 817 | 0.590 |
Why?
|
| Calpain | 3 | 2009 | 146 | 0.560 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 4 | 2023 | 48 | 0.550 |
Why?
|
| Stiff-Person Syndrome | 2 | 2012 | 31 | 0.530 |
Why?
|
| Creatine Kinase | 11 | 2019 | 685 | 0.520 |
Why?
|
| Boronic Acids | 3 | 2009 | 915 | 0.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3245 | 0.490 |
Why?
|
| Authorship | 1 | 2018 | 284 | 0.480 |
Why?
|
| Electromyography | 11 | 2019 | 1394 | 0.480 |
Why?
|
| Visual Acuity | 1 | 2024 | 2672 | 0.470 |
Why?
|
| Myotonia | 5 | 2014 | 18 | 0.460 |
Why?
|
| Muscle Strength | 6 | 2021 | 624 | 0.450 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2013 | 195 | 0.450 |
Why?
|
| Pyrazines | 3 | 2009 | 1201 | 0.440 |
Why?
|
| Paresthesia | 2 | 2013 | 162 | 0.440 |
Why?
|
| Disease Management | 3 | 2024 | 2508 | 0.430 |
Why?
|
| Coffee | 1 | 2017 | 593 | 0.430 |
Why?
|
| Middle Aged | 112 | 2024 | 220895 | 0.420 |
Why?
|
| Caffeine | 1 | 2017 | 700 | 0.420 |
Why?
|
| Demyelinating Diseases | 4 | 2004 | 351 | 0.420 |
Why?
|
| Antibodies | 6 | 2009 | 2418 | 0.420 |
Why?
|
| Muscle Fibers, Skeletal | 5 | 2009 | 542 | 0.420 |
Why?
|
| Receptors, Cholinergic | 3 | 2022 | 244 | 0.420 |
Why?
|
| Electrophysiology | 4 | 2012 | 1262 | 0.410 |
Why?
|
| Eosinophilia | 2 | 2008 | 560 | 0.410 |
Why?
|
| Enzyme Inhibitors | 2 | 2020 | 3712 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 1880 | 0.400 |
Why?
|
| Sural Nerve | 6 | 2004 | 105 | 0.390 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 2 | 2020 | 24 | 0.380 |
Why?
|
| Adult | 107 | 2024 | 221177 | 0.380 |
Why?
|
| Autoantibodies | 6 | 2024 | 2116 | 0.370 |
Why?
|
| Pain | 5 | 2020 | 5073 | 0.370 |
Why?
|
| Male | 134 | 2024 | 360804 | 0.370 |
Why?
|
| Publishing | 1 | 2018 | 833 | 0.360 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 240 | 0.360 |
Why?
|
| Female | 130 | 2024 | 392644 | 0.360 |
Why?
|
| Thymectomy | 4 | 2020 | 195 | 0.350 |
Why?
|
| Gangliosides | 1 | 2010 | 132 | 0.340 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1784 | 0.340 |
Why?
|
| Spinal Cord Diseases | 1 | 2012 | 292 | 0.340 |
Why?
|
| Myofibrils | 3 | 2014 | 141 | 0.330 |
Why?
|
| Drainage | 2 | 2013 | 1157 | 0.330 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 357 | 0.320 |
Why?
|
| Membrane Proteins | 6 | 2011 | 7856 | 0.320 |
Why?
|
| Exercise Tolerance | 3 | 2003 | 836 | 0.320 |
Why?
|
| Time | 2 | 2021 | 546 | 0.320 |
Why?
|
| Enzyme Therapy | 1 | 2008 | 8 | 0.320 |
Why?
|
| alpha-Glucosidases | 1 | 2008 | 45 | 0.310 |
Why?
|
| Aged | 82 | 2022 | 169289 | 0.300 |
Why?
|
| Ganglia, Spinal | 1 | 2010 | 526 | 0.300 |
Why?
|
| Muscles | 10 | 2016 | 1576 | 0.290 |
Why?
|
| Myostatin | 1 | 2009 | 129 | 0.290 |
Why?
|
| Interferon-beta | 3 | 2007 | 345 | 0.290 |
Why?
|
| Diagnosis, Differential | 17 | 2018 | 12974 | 0.290 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2013 | 1033 | 0.280 |
Why?
|
| Vacuoles | 2 | 2013 | 228 | 0.280 |
Why?
|
| Aged, 80 and over | 30 | 2021 | 58976 | 0.280 |
Why?
|
| Muscle Contraction | 3 | 2022 | 1201 | 0.280 |
Why?
|
| Nervous System Diseases | 4 | 2021 | 1666 | 0.280 |
Why?
|
| Persian Gulf Syndrome | 2 | 1997 | 47 | 0.280 |
Why?
|
| Endocrine System Diseases | 1 | 2009 | 249 | 0.270 |
Why?
|
| Interferon-alpha | 4 | 2013 | 921 | 0.270 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 2 | 1996 | 21 | 0.270 |
Why?
|
| Immunotherapy | 6 | 2024 | 4652 | 0.260 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2009 | 1469 | 0.260 |
Why?
|
| Carnitine | 4 | 2001 | 252 | 0.260 |
Why?
|
| Sensory Receptor Cells | 1 | 2010 | 513 | 0.260 |
Why?
|
| Disease Progression | 9 | 2023 | 13506 | 0.260 |
Why?
|
| Genetic Testing | 3 | 2016 | 3537 | 0.250 |
Why?
|
| Necrosis | 3 | 2024 | 1611 | 0.250 |
Why?
|
| Double-Blind Method | 15 | 2023 | 12341 | 0.250 |
Why?
|
| Toxins, Biological | 1 | 2005 | 60 | 0.250 |
Why?
|
| Immune System | 1 | 2010 | 796 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2010 | 1626 | 0.230 |
Why?
|
| Societies, Medical | 6 | 2017 | 3905 | 0.230 |
Why?
|
| Mononeuropathies | 1 | 2004 | 13 | 0.230 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2024 | 60 | 0.230 |
Why?
|
| Plasma Cells | 3 | 2010 | 599 | 0.230 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2003 | 8 | 0.230 |
Why?
|
| Greenhouse Effect | 1 | 2004 | 31 | 0.230 |
Why?
|
| Immunization, Passive | 2 | 2022 | 616 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 9177 | 0.220 |
Why?
|
| Frameshift Mutation | 1 | 2005 | 392 | 0.220 |
Why?
|
| Sucrose | 1 | 2003 | 158 | 0.220 |
Why?
|
| Peripheral Nerves | 4 | 2021 | 479 | 0.210 |
Why?
|
| Motor Neuron Disease | 5 | 2013 | 97 | 0.210 |
Why?
|
| Cyclin D1 | 1 | 2005 | 451 | 0.210 |
Why?
|
| Intermittent Claudication | 3 | 2001 | 304 | 0.210 |
Why?
|
| Rheumatology | 3 | 2017 | 615 | 0.210 |
Why?
|
| Receptors, CCR5 | 1 | 2005 | 486 | 0.210 |
Why?
|
| Dyspnea | 1 | 2011 | 1347 | 0.210 |
Why?
|
| Medicine | 1 | 2011 | 942 | 0.210 |
Why?
|
| Myotonic Disorders | 2 | 2014 | 7 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 2 | 2022 | 831 | 0.210 |
Why?
|
| Immunohistochemistry | 13 | 2014 | 11076 | 0.210 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2022 | 21 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2017 | 1809 | 0.200 |
Why?
|
| Treatment Outcome | 25 | 2023 | 64680 | 0.200 |
Why?
|
| Median Nerve | 4 | 2019 | 132 | 0.200 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 683 | 0.200 |
Why?
|
| Neuromuscular Junction Diseases | 3 | 2015 | 14 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.200 |
Why?
|
| Prealbumin | 1 | 2004 | 222 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.200 |
Why?
|
| Hypesthesia | 2 | 2018 | 107 | 0.200 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2001 | 32 | 0.200 |
Why?
|
| Industry | 1 | 2004 | 364 | 0.190 |
Why?
|
| Lectins, C-Type | 3 | 2019 | 585 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 2 | 2008 | 2693 | 0.190 |
Why?
|
| Inflammation | 3 | 2018 | 10773 | 0.190 |
Why?
|
| Multiple Myeloma | 3 | 2009 | 5146 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2010 | 3778 | 0.190 |
Why?
|
| Conservation of Natural Resources | 1 | 2004 | 211 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 7390 | 0.190 |
Why?
|
| Technology | 1 | 2004 | 292 | 0.190 |
Why?
|
| Consensus | 7 | 2023 | 3123 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2017 | 186 | 0.190 |
Why?
|
| Dystrophin | 4 | 2006 | 283 | 0.190 |
Why?
|
| Ganglia, Sensory | 1 | 2020 | 19 | 0.180 |
Why?
|
| Ganglia, Autonomic | 1 | 2021 | 43 | 0.180 |
Why?
|
| Graft vs Host Disease | 2 | 2009 | 3029 | 0.180 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 4111 | 0.180 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 1600 | 0.180 |
Why?
|
| Muscular Atrophy | 2 | 2014 | 334 | 0.180 |
Why?
|
| Mutation | 16 | 2016 | 30052 | 0.180 |
Why?
|
| Glucan 1,4-alpha-Glucosidase | 1 | 2000 | 8 | 0.180 |
Why?
|
| Infusions, Subcutaneous | 1 | 2020 | 43 | 0.180 |
Why?
|
| Myasthenic Syndromes, Congenital | 1 | 2020 | 17 | 0.170 |
Why?
|
| Antibodies, Antinuclear | 1 | 2001 | 343 | 0.170 |
Why?
|
| Severity of Illness Index | 8 | 2019 | 15842 | 0.170 |
Why?
|
| Meningitis | 1 | 2001 | 217 | 0.170 |
Why?
|
| Glycogen Storage Disease | 1 | 2000 | 41 | 0.170 |
Why?
|
| Vasospasm, Intracranial | 2 | 2013 | 215 | 0.170 |
Why?
|
| Agrin | 1 | 2020 | 75 | 0.170 |
Why?
|
| Receptors, GABA-A | 3 | 1999 | 623 | 0.170 |
Why?
|
| Receptors, Nicotinic | 2 | 2020 | 495 | 0.170 |
Why?
|
| Models, Economic | 1 | 2004 | 716 | 0.170 |
Why?
|
| Sulfhydryl Reagents | 1 | 1999 | 32 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 420 | 0.170 |
Why?
|
| Cytokines | 5 | 2017 | 7396 | 0.160 |
Why?
|
| Myopathies, Structural, Congenital | 3 | 2016 | 103 | 0.160 |
Why?
|
| Genes, cdc | 1 | 2019 | 114 | 0.160 |
Why?
|
| Dependovirus | 1 | 2024 | 718 | 0.160 |
Why?
|
| Methylprednisolone | 1 | 2020 | 385 | 0.160 |
Why?
|
| Adolescent | 35 | 2024 | 88319 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 231 | 0.160 |
Why?
|
| Carpal Tunnel Syndrome | 2 | 2019 | 303 | 0.160 |
Why?
|
| Macrolides | 1 | 2020 | 205 | 0.160 |
Why?
|
| Self Administration | 1 | 2020 | 390 | 0.160 |
Why?
|
| Receptors, Immunologic | 3 | 2019 | 1410 | 0.160 |
Why?
|
| Riboflavin | 1 | 2019 | 107 | 0.160 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 237 | 0.160 |
Why?
|
| Chloroquine | 1 | 2020 | 274 | 0.160 |
Why?
|
| Italy | 7 | 2023 | 842 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2022 | 36426 | 0.150 |
Why?
|
| House Calls | 1 | 2020 | 161 | 0.150 |
Why?
|
| Brachial Plexus Neuritis | 1 | 2018 | 20 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2005 | 3606 | 0.150 |
Why?
|
| Exercise Test | 4 | 2014 | 2127 | 0.150 |
Why?
|
| Alanine | 1 | 2020 | 609 | 0.150 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 613 | 0.150 |
Why?
|
| Environment | 1 | 2004 | 1123 | 0.150 |
Why?
|
| Neurologic Examination | 5 | 2013 | 916 | 0.150 |
Why?
|
| Scleroderma, Systemic | 1 | 2001 | 344 | 0.150 |
Why?
|
| MEDLINE | 1 | 2017 | 119 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1085 | 0.150 |
Why?
|
| Retrospective Studies | 30 | 2024 | 80636 | 0.150 |
Why?
|
| Visual Fields | 1 | 2024 | 1062 | 0.140 |
Why?
|
| Asymptomatic Infections | 1 | 2018 | 131 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2021 | 343 | 0.140 |
Why?
|
| Diverticulitis, Colonic | 1 | 2018 | 138 | 0.140 |
Why?
|
| Brachial Plexus | 2 | 2001 | 167 | 0.140 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2208 | 0.140 |
Why?
|
| Twins | 1 | 1998 | 339 | 0.140 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 299 | 0.140 |
Why?
|
| Autoantigens | 4 | 2013 | 891 | 0.140 |
Why?
|
| Child | 28 | 2024 | 80153 | 0.140 |
Why?
|
| Gene Expression Profiling | 4 | 2012 | 9420 | 0.130 |
Why?
|
| Inclusion Bodies | 2 | 1995 | 281 | 0.130 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1998 | 155 | 0.130 |
Why?
|
| Vaccination | 2 | 2023 | 3384 | 0.130 |
Why?
|
| Upper Extremity | 2 | 2019 | 657 | 0.130 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2016 | 24 | 0.130 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2015 | 8 | 0.130 |
Why?
|
| Neurons | 4 | 2013 | 9463 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.130 |
Why?
|
| Young Adult | 21 | 2024 | 59243 | 0.130 |
Why?
|
| Colonoscopy | 3 | 2020 | 1394 | 0.130 |
Why?
|
| Sarcoplasmic Reticulum | 3 | 2014 | 163 | 0.130 |
Why?
|
| Hydroxyethylrutoside | 1 | 2015 | 4 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 2021 | 865 | 0.130 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 80 | 0.130 |
Why?
|
| Diosmin | 1 | 2015 | 6 | 0.130 |
Why?
|
| Neurosciences | 1 | 2020 | 367 | 0.130 |
Why?
|
| Hemorrhoids | 1 | 2015 | 19 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2011 | 4792 | 0.130 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1995 | 49 | 0.130 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 48 | 0.120 |
Why?
|
| Hesperidin | 1 | 2015 | 18 | 0.120 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 161 | 0.120 |
Why?
|
| Paralyses, Familial Periodic | 1 | 2014 | 13 | 0.120 |
Why?
|
| Pharyngeal Muscles | 1 | 1995 | 81 | 0.120 |
Why?
|
| Chloride Channels | 2 | 2013 | 221 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2024 | 3395 | 0.120 |
Why?
|
| Channelopathies | 1 | 2014 | 30 | 0.120 |
Why?
|
| Autoimmunity | 2 | 2013 | 1356 | 0.120 |
Why?
|
| Fatigue | 3 | 2018 | 1552 | 0.120 |
Why?
|
| Viral Vaccines | 1 | 2020 | 596 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 9280 | 0.120 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 1897 | 0.120 |
Why?
|
| Alleles | 2 | 2005 | 6863 | 0.120 |
Why?
|
| Smad2 Protein | 1 | 2014 | 145 | 0.120 |
Why?
|
| Smad3 Protein | 1 | 2014 | 166 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1996 | 418 | 0.120 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2915 | 0.120 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 243 | 0.110 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 123 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1285 | 0.110 |
Why?
|
| Antiviral Agents | 3 | 2020 | 3060 | 0.110 |
Why?
|
| Picolines | 1 | 2013 | 10 | 0.110 |
Why?
|
| Axons | 1 | 2002 | 1674 | 0.110 |
Why?
|
| Age of Onset | 6 | 2013 | 3305 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2014 | 97 | 0.110 |
Why?
|
| Colorectal Surgery | 2 | 2012 | 122 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2004 | 2220 | 0.110 |
Why?
|
| Colonic Polyps | 1 | 2018 | 554 | 0.110 |
Why?
|
| Facial Transplantation | 1 | 2016 | 221 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 1112 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2001 | 1818 | 0.110 |
Why?
|
| Retina | 1 | 2024 | 2659 | 0.110 |
Why?
|
| Thigh | 1 | 2014 | 241 | 0.110 |
Why?
|
| Citrates | 1 | 2013 | 134 | 0.110 |
Why?
|
| Lower Extremity | 2 | 2019 | 1202 | 0.110 |
Why?
|
| Observer Variation | 1 | 2019 | 2606 | 0.110 |
Why?
|
| Mycophenolic Acid | 2 | 2006 | 348 | 0.110 |
Why?
|
| Accidental Falls | 1 | 2021 | 1068 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2005 | 4414 | 0.100 |
Why?
|
| Mutation, Missense | 2 | 2020 | 2571 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2014 | 282 | 0.100 |
Why?
|
| Shoulder Pain | 1 | 2014 | 151 | 0.100 |
Why?
|
| Anastomotic Leak | 1 | 2014 | 163 | 0.100 |
Why?
|
| Muscle Cells | 2 | 2012 | 195 | 0.100 |
Why?
|
| Cathartics | 1 | 2013 | 127 | 0.100 |
Why?
|
| Celiac Disease | 1 | 2020 | 821 | 0.100 |
Why?
|
| Dynamin II | 1 | 2012 | 35 | 0.100 |
Why?
|
| Insurance Claim Reporting | 1 | 2013 | 166 | 0.100 |
Why?
|
| Amides | 2 | 2008 | 449 | 0.100 |
Why?
|
| Chromosome Mapping | 4 | 2011 | 4615 | 0.100 |
Why?
|
| Quadriceps Muscle | 1 | 2013 | 156 | 0.100 |
Why?
|
| Cell Nucleus | 3 | 2014 | 2909 | 0.100 |
Why?
|
| Stents | 4 | 2014 | 3179 | 0.100 |
Why?
|
| 5'-Nucleotidase | 1 | 2013 | 161 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 5796 | 0.100 |
Why?
|
| Medical Records | 3 | 2013 | 1408 | 0.100 |
Why?
|
| Antineoplastic Agents | 5 | 2009 | 13639 | 0.100 |
Why?
|
| Pandemics | 2 | 2023 | 8654 | 0.100 |
Why?
|
| Research | 1 | 2020 | 1982 | 0.100 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 372 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 2538 | 0.090 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2015 | 328 | 0.090 |
Why?
|
| Organ Size | 2 | 2014 | 2254 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 1995 | 406 | 0.090 |
Why?
|
| Phenotype | 6 | 2019 | 16591 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 2273 | 0.090 |
Why?
|
| Dystroglycans | 1 | 2011 | 62 | 0.090 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 8002 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 598 | 0.090 |
Why?
|
| Medicare Part B | 1 | 2012 | 117 | 0.090 |
Why?
|
| Membrane Glycoproteins | 4 | 2007 | 3702 | 0.090 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2011 | 38 | 0.090 |
Why?
|
| Rectal Neoplasms | 2 | 2008 | 1157 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1271 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 1640 | 0.090 |
Why?
|
| Genes, Recessive | 1 | 2013 | 623 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2013 | 727 | 0.090 |
Why?
|
| Physical Examination | 2 | 2012 | 1255 | 0.090 |
Why?
|
| Peroneal Nerve | 3 | 2000 | 76 | 0.090 |
Why?
|
| Biomedical Technology | 1 | 2012 | 211 | 0.090 |
Why?
|
| Myelin Proteins | 1 | 2011 | 209 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2013 | 655 | 0.090 |
Why?
|
| Air Pollution | 1 | 2004 | 2359 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2016 | 2161 | 0.090 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 647 | 0.080 |
Why?
|
| Glycogen | 2 | 2003 | 251 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2014 | 8320 | 0.080 |
Why?
|
| Microscopy, Electron | 2 | 2006 | 2561 | 0.080 |
Why?
|
| Sarcomeres | 2 | 2009 | 368 | 0.080 |
Why?
|
| Animals | 19 | 2023 | 168459 | 0.080 |
Why?
|
| Myopathies, Nemaline | 1 | 2010 | 73 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 6935 | 0.080 |
Why?
|
| Hand Strength | 1 | 2012 | 456 | 0.080 |
Why?
|
| Exanthema | 2 | 2016 | 503 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2010 | 4758 | 0.080 |
Why?
|
| X Chromosome | 1 | 1993 | 816 | 0.080 |
Why?
|
| Lysine Carboxypeptidase | 1 | 1989 | 2 | 0.080 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2013 | 569 | 0.080 |
Why?
|
| Myelitis, Transverse | 2 | 2013 | 40 | 0.080 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2009 | 70 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2012 | 852 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2001 | 1924 | 0.080 |
Why?
|
| Intracranial Pressure | 1 | 2011 | 324 | 0.080 |
Why?
|
| Microdissection | 4 | 2010 | 151 | 0.080 |
Why?
|
| Single-Blind Method | 3 | 2020 | 1572 | 0.080 |
Why?
|
| Diverticulitis | 1 | 2011 | 185 | 0.080 |
Why?
|
| Proteomics | 4 | 2010 | 3849 | 0.080 |
Why?
|
| Skin | 1 | 2023 | 4484 | 0.080 |
Why?
|
| Microscopy, Immunoelectron | 2 | 2007 | 317 | 0.080 |
Why?
|
| Carboxypeptidases | 1 | 1989 | 154 | 0.080 |
Why?
|
| Desmin | 3 | 2012 | 99 | 0.080 |
Why?
|
| Thymus Neoplasms | 2 | 2022 | 274 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 582 | 0.080 |
Why?
|
| Aminopeptidases | 1 | 1989 | 95 | 0.080 |
Why?
|
| Placebos | 2 | 2013 | 1667 | 0.080 |
Why?
|
| Syndecan-1 | 2 | 2007 | 163 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 3826 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2019 | 11528 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 445 | 0.080 |
Why?
|
| Ubiquitins | 1 | 2010 | 366 | 0.080 |
Why?
|
| United States | 14 | 2023 | 72334 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 606 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2016 | 4003 | 0.080 |
Why?
|
| Gene Deletion | 1 | 1996 | 2665 | 0.080 |
Why?
|
| Child, Preschool | 12 | 2021 | 42230 | 0.080 |
Why?
|
| Autonomic Nervous System | 1 | 2013 | 703 | 0.070 |
Why?
|
| Voice | 1 | 2011 | 268 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 736 | 0.070 |
Why?
|
| Leukocytes | 2 | 2013 | 2026 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2014 | 5671 | 0.070 |
Why?
|
| Telephone | 1 | 2011 | 627 | 0.070 |
Why?
|
| Enzymes | 1 | 2009 | 257 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 1189 | 0.070 |
Why?
|
| Glycosylation | 1 | 2011 | 1098 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 452 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 1993 | 2341 | 0.070 |
Why?
|
| GTP Phosphohydrolases | 1 | 2011 | 517 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 572 | 0.070 |
Why?
|
| GTP-Binding Proteins | 3 | 2007 | 951 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 1372 | 0.070 |
Why?
|
| Immunoglobulin Switch Region | 1 | 2007 | 44 | 0.070 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 4544 | 0.070 |
Why?
|
| Dendritic Cells | 3 | 2010 | 2747 | 0.070 |
Why?
|
| Technetium | 1 | 2007 | 317 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1989 | 362 | 0.070 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2007 | 57 | 0.070 |
Why?
|
| MicroRNAs | 3 | 2014 | 3816 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 2010 | 853 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 1079 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 9606 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2012 | 940 | 0.070 |
Why?
|
| Europe | 3 | 2017 | 3422 | 0.070 |
Why?
|
| Health Resources | 1 | 2012 | 935 | 0.070 |
Why?
|
| Syndecans | 1 | 2005 | 75 | 0.070 |
Why?
|
| Prospective Studies | 11 | 2018 | 54425 | 0.070 |
Why?
|
| Motor Neurons | 5 | 2003 | 870 | 0.070 |
Why?
|
| Immunization | 1 | 2010 | 1228 | 0.060 |
Why?
|
| Sicily | 1 | 2005 | 10 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 1063 | 0.060 |
Why?
|
| Biological Assay | 1 | 2009 | 626 | 0.060 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2006 | 140 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2005 | 960 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4580 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 754 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 3416 | 0.060 |
Why?
|
| Lamin Type A | 1 | 2006 | 189 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 6534 | 0.060 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2007 | 239 | 0.060 |
Why?
|
| Phosphorus Radioisotopes | 3 | 2000 | 100 | 0.060 |
Why?
|
| Tramadol | 1 | 2006 | 60 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2010 | 617 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2006 | 128 | 0.060 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2005 | 50 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3466 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1755 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 2008 | 335 | 0.060 |
Why?
|
| Capillaries | 2 | 2007 | 755 | 0.060 |
Why?
|
| Antigens, Surface | 2 | 2007 | 1606 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 976 | 0.060 |
Why?
|
| Ultrasonography | 3 | 2019 | 5972 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2012 | 768 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 686 | 0.060 |
Why?
|
| RNA, Messenger | 6 | 2012 | 12795 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2023 | 8631 | 0.060 |
Why?
|
| Steel | 1 | 2004 | 27 | 0.060 |
Why?
|
| Blood Vessels | 2 | 2012 | 1113 | 0.060 |
Why?
|
| Ethylenes | 1 | 2004 | 43 | 0.060 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2004 | 105 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5709 | 0.060 |
Why?
|
| Infant | 8 | 2014 | 36192 | 0.060 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 14666 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 2007 | 11903 | 0.060 |
Why?
|
| Sarcolemma | 2 | 2020 | 65 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 1374 | 0.060 |
Why?
|
| Viremia | 2 | 2018 | 707 | 0.060 |
Why?
|
| Glycolysis | 2 | 2009 | 835 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2012 | 1161 | 0.060 |
Why?
|
| Paper | 1 | 2004 | 84 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2005 | 168 | 0.060 |
Why?
|
| Cell Movement | 2 | 2013 | 5203 | 0.060 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2007 | 545 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 1779 | 0.060 |
Why?
|
| Anastomosis, Surgical | 3 | 2014 | 983 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2009 | 1567 | 0.050 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2003 | 52 | 0.050 |
Why?
|
| beta-Thalassemia | 2 | 1997 | 236 | 0.050 |
Why?
|
| Logistic Models | 5 | 2017 | 13255 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 835 | 0.050 |
Why?
|
| Neoplasms | 3 | 2003 | 22170 | 0.050 |
Why?
|
| Anesthetics, General | 1 | 2005 | 151 | 0.050 |
Why?
|
| Vinculin | 1 | 2003 | 59 | 0.050 |
Why?
|
| Talin | 1 | 2003 | 47 | 0.050 |
Why?
|
| Reference Values | 4 | 2017 | 4920 | 0.050 |
Why?
|
| DNA | 2 | 1996 | 7212 | 0.050 |
Why?
|
| Apoptosis | 1 | 1999 | 9486 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 3461 | 0.050 |
Why?
|
| Anesthetics, Intravenous | 1 | 2006 | 395 | 0.050 |
Why?
|
| Radial Nerve | 3 | 1999 | 42 | 0.050 |
Why?
|
| International Classification of Diseases | 3 | 2013 | 909 | 0.050 |
Why?
|
| Mice | 12 | 2023 | 81525 | 0.050 |
Why?
|
| Ulnar Nerve | 3 | 1999 | 102 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2735 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3051 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2005 | 803 | 0.050 |
Why?
|
| Caveolae | 1 | 2022 | 55 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3201 | 0.050 |
Why?
|
| Brachytherapy | 2 | 2000 | 1223 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 411 | 0.050 |
Why?
|
| Gait Ataxia | 1 | 2001 | 11 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5336 | 0.050 |
Why?
|
| Sorbitol | 1 | 2021 | 57 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2007 | 823 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2004 | 248 | 0.050 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2003 | 215 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8529 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2009 | 2767 | 0.050 |
Why?
|
| Rectum | 2 | 2020 | 892 | 0.050 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 410 | 0.050 |
Why?
|
| Hospitalization | 2 | 2018 | 10723 | 0.050 |
Why?
|
| Intercalating Agents | 1 | 2001 | 33 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 997 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2008 | 1119 | 0.050 |
Why?
|
| Acetylcarnitine | 1 | 2000 | 9 | 0.050 |
Why?
|
| Baclofen | 1 | 2021 | 120 | 0.050 |
Why?
|
| Arm | 3 | 2018 | 589 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2022 | 2244 | 0.040 |
Why?
|
| Age Factors | 5 | 2012 | 18395 | 0.040 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 10194 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2005 | 1089 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2013 | 7967 | 0.040 |
Why?
|
| Acute Disease | 3 | 2018 | 7237 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2023 | 450 | 0.040 |
Why?
|
| Tibial Nerve | 2 | 1999 | 50 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2001 | 140 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2006 | 1181 | 0.040 |
Why?
|
| Policy Making | 1 | 2004 | 542 | 0.040 |
Why?
|
| Adenine | 1 | 2006 | 987 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2007 | 2555 | 0.040 |
Why?
|
| Prognosis | 5 | 2010 | 29625 | 0.040 |
Why?
|
| Propofol | 1 | 2006 | 603 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 2 | 1999 | 927 | 0.040 |
Why?
|
| Dithionitrobenzoic Acid | 1 | 1999 | 20 | 0.040 |
Why?
|
| Constriction, Pathologic | 2 | 2014 | 1096 | 0.040 |
Why?
|
| Pedigree | 3 | 2014 | 4542 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2009 | 9318 | 0.040 |
Why?
|
| Cell Line | 5 | 2014 | 15601 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 2578 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 1463 | 0.040 |
Why?
|
| Action Potentials | 2 | 1997 | 1834 | 0.040 |
Why?
|
| Acetates | 1 | 2001 | 321 | 0.040 |
Why?
|
| Dithiothreitol | 1 | 1999 | 93 | 0.040 |
Why?
|
| Methotrexate | 2 | 2016 | 1719 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2001 | 1834 | 0.040 |
Why?
|
| Lyme Disease | 1 | 2005 | 631 | 0.040 |
Why?
|
| Recurrence | 5 | 2011 | 8465 | 0.040 |
Why?
|
| Amines | 1 | 2001 | 281 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2015 | 4812 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2003 | 708 | 0.040 |
Why?
|
| Multigene Family | 1 | 2002 | 1076 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2001 | 352 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2012 | 3242 | 0.040 |
Why?
|
| Mass Spectrometry | 3 | 2013 | 2192 | 0.040 |
Why?
|
| Uncertainty | 1 | 2004 | 754 | 0.040 |
Why?
|
| Naltrexone | 1 | 2021 | 317 | 0.040 |
Why?
|
| Hallucinations | 1 | 2001 | 366 | 0.040 |
Why?
|
| Radiculopathy | 1 | 2001 | 202 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2510 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2011 | 2053 | 0.040 |
Why?
|
| tau Proteins | 1 | 2009 | 2095 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2023 | 597 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2009 | 1157 | 0.040 |
Why?
|
| Incidence | 7 | 2012 | 21353 | 0.040 |
Why?
|
| Cluster Analysis | 3 | 2012 | 2707 | 0.040 |
Why?
|
| Medicaid | 1 | 2012 | 2818 | 0.040 |
Why?
|
| Thymoma | 1 | 2020 | 188 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 2003 | 405 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 237 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2012 | 2919 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 1989 | 1459 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2004 | 2155 | 0.040 |
Why?
|
| Integrins | 1 | 2003 | 834 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3530 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2007 | 2612 | 0.040 |
Why?
|
| Prostaglandins | 1 | 1999 | 398 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 10766 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4575 | 0.040 |
Why?
|
| Dermis | 1 | 1999 | 202 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 5486 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 1739 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 2469 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4591 | 0.040 |
Why?
|
| Gene Expression | 4 | 2014 | 7581 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2014 | 18965 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2020 | 405 | 0.040 |
Why?
|
| Neuralgia | 1 | 2004 | 615 | 0.040 |
Why?
|
| Probability | 2 | 2017 | 2477 | 0.040 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2017 | 51 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 1008 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2001 | 1141 | 0.040 |
Why?
|
| Piperidines | 1 | 2006 | 1656 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 13380 | 0.040 |
Why?
|
| Distal Myopathies | 1 | 2016 | 18 | 0.030 |
Why?
|
| Up-Regulation | 3 | 2012 | 4124 | 0.030 |
Why?
|
| Cohort Studies | 7 | 2014 | 41487 | 0.030 |
Why?
|
| Vitamin E Deficiency | 1 | 1996 | 30 | 0.030 |
Why?
|
| Spinocerebellar Degenerations | 1 | 1996 | 44 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1998 | 337 | 0.030 |
Why?
|
| Genomics | 1 | 2012 | 5821 | 0.030 |
Why?
|
| Globins | 1 | 1997 | 404 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2000 | 2898 | 0.030 |
Why?
|
| Age Distribution | 2 | 2012 | 2880 | 0.030 |
Why?
|
| Vasculitis | 1 | 2000 | 521 | 0.030 |
Why?
|
| Seasons | 2 | 2012 | 1520 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2016 | 53 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5821 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2001 | 803 | 0.030 |
Why?
|
| Goiter, Substernal | 1 | 1995 | 17 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 3448 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 1999 | 1090 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1998 | 484 | 0.030 |
Why?
|
| Pain Measurement | 3 | 2015 | 3550 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4352 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 20098 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1996 | 287 | 0.030 |
Why?
|
| Netherlands | 2 | 2014 | 2221 | 0.030 |
Why?
|
| Medical Audit | 1 | 2017 | 453 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2016 | 252 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 1738 | 0.030 |
Why?
|
| Chromatography, Liquid | 2 | 2009 | 983 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 625 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 416 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2000 | 5914 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 1999 | 639 | 0.030 |
Why?
|
| Iron | 1 | 2004 | 1793 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2001 | 980 | 0.030 |
Why?
|
| Registries | 2 | 2023 | 8224 | 0.030 |
Why?
|
| Lymphocytosis | 1 | 2016 | 121 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 1302 | 0.030 |
Why?
|
| Azathioprine | 1 | 1996 | 354 | 0.030 |
Why?
|
| Amino Acid Sequence | 5 | 2012 | 13446 | 0.030 |
Why?
|
| Vasodilation | 1 | 1999 | 962 | 0.030 |
Why?
|
| Rectal Prolapse | 1 | 2015 | 33 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2008 | 15631 | 0.030 |
Why?
|
| Brain | 3 | 2005 | 27112 | 0.030 |
Why?
|
| Survival Rate | 4 | 2014 | 12725 | 0.030 |
Why?
|
| Mitochondria, Muscle | 1 | 1995 | 172 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2012 | 23995 | 0.030 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2014 | 30 | 0.030 |
Why?
|
| Risk Factors | 6 | 2017 | 74206 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2007 | 2279 | 0.030 |
Why?
|
| Rats | 3 | 2020 | 23742 | 0.030 |
Why?
|
| Weight Loss | 1 | 2006 | 2684 | 0.030 |
Why?
|
| Research Design | 2 | 2015 | 6180 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 603 | 0.030 |
Why?
|
| Arteries | 1 | 1999 | 1123 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5305 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 14605 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1999 | 894 | 0.030 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 38 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4740 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 5789 | 0.030 |
Why?
|
| Mexiletine | 1 | 2013 | 30 | 0.030 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2016 | 267 | 0.030 |
Why?
|
| Atrophy | 1 | 1999 | 1633 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 3613 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 1995 | 472 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 545 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 6346 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1008 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 1638 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 4853 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1993 | 72 | 0.030 |
Why?
|
| Manometry | 1 | 1996 | 454 | 0.030 |
Why?
|
| Extremities | 1 | 1999 | 867 | 0.030 |
Why?
|
| Smad5 Protein | 1 | 2013 | 26 | 0.030 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1251 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 1725 | 0.030 |
Why?
|
| Anal Canal | 1 | 1996 | 373 | 0.030 |
Why?
|
| Heterozygote | 2 | 2006 | 2787 | 0.030 |
Why?
|
| Impotence, Vasculogenic | 1 | 2012 | 12 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2016 | 22176 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 1126 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 235 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 2231 | 0.030 |
Why?
|
| Delirium | 1 | 2005 | 1668 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 2421 | 0.030 |
Why?
|
| Spermatic Cord | 1 | 2012 | 23 | 0.030 |
Why?
|
| International Cooperation | 2 | 2013 | 1422 | 0.030 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2012 | 34 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1995 | 488 | 0.030 |
Why?
|
| Proteins | 1 | 2007 | 6032 | 0.030 |
Why?
|
| Obesity | 2 | 2006 | 12947 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1996 | 323 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 1996 | 1989 | 0.030 |
Why?
|
| Linear Models | 1 | 2002 | 5871 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 1998 | 823 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2013 | 205 | 0.030 |
Why?
|
| Photoplethysmography | 1 | 2012 | 60 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15266 | 0.030 |
Why?
|
| Algorithms | 1 | 2013 | 14031 | 0.030 |
Why?
|
| Neurons, Afferent | 3 | 2001 | 498 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2014 | 562 | 0.030 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2014 | 177 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 283 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2013 | 298 | 0.020 |
Why?
|
| Myosins | 1 | 2013 | 405 | 0.020 |
Why?
|
| Time Factors | 4 | 2016 | 39967 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1997 | 2218 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 344 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 17635 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2012 | 163 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 2014 | 406 | 0.020 |
Why?
|
| Meningococcal Vaccines | 1 | 2012 | 94 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 6814 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2013 | 285 | 0.020 |
Why?
|
| Thioglycolates | 1 | 1991 | 37 | 0.020 |
Why?
|
| Fragile X Syndrome | 1 | 1993 | 116 | 0.020 |
Why?
|
| Surgical Stomas | 1 | 2011 | 42 | 0.020 |
Why?
|
| Genitalia, Female | 1 | 2012 | 147 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2012 | 179 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2012 | 248 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 368 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 17351 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 756 | 0.020 |
Why?
|
| Penis | 1 | 2012 | 212 | 0.020 |
Why?
|
| Clinical Coding | 1 | 2013 | 181 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 1991 | 34 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1996 | 1386 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 2012 | 329 | 0.020 |
Why?
|
| Kinetics | 1 | 1999 | 6374 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 435 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1999 | 3968 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 506 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2014 | 749 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2013 | 286 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2013 | 2242 | 0.020 |
Why?
|
| Tyrosine | 1 | 1995 | 1440 | 0.020 |
Why?
|
| Myocardium | 2 | 2007 | 4726 | 0.020 |
Why?
|
| Adenoma | 2 | 2018 | 2160 | 0.020 |
Why?
|
| Pancreatitis, Chronic | 1 | 2014 | 289 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2013 | 638 | 0.020 |
Why?
|
| HIV | 1 | 2018 | 1582 | 0.020 |
Why?
|
| Life Tables | 1 | 1991 | 364 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1999 | 1230 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 785 | 0.020 |
Why?
|
| Isometric Contraction | 2 | 2005 | 150 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2012 | 339 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2012 | 328 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4278 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 856 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2005 | 3979 | 0.020 |
Why?
|
| Brain Injury, Chronic | 1 | 2011 | 68 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 11121 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2015 | 1736 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 878 | 0.020 |
Why?
|
| Eye Diseases | 1 | 2016 | 653 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 115 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1851 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 625 | 0.020 |
Why?
|
| Siblings | 1 | 2014 | 825 | 0.020 |
Why?
|
| Pelvic Pain | 1 | 2012 | 298 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2001 | 329 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2021 | 2521 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 1991 | 217 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2012 | 326 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2023 | 26198 | 0.020 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2009 | 13 | 0.020 |
Why?
|
| Cytosol | 1 | 2013 | 888 | 0.020 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 1993 | 258 | 0.020 |
Why?
|
| Congo Red | 1 | 2009 | 48 | 0.020 |
Why?
|
| Psychometrics | 1 | 2019 | 3065 | 0.020 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2010 | 149 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2005 | 10445 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2012 | 911 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 283 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 3032 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2010 | 158 | 0.020 |
Why?
|
| Device Removal | 1 | 2014 | 630 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2016 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2010 | 445 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2015 | 2048 | 0.020 |
Why?
|
| Choristoma | 1 | 2010 | 206 | 0.020 |
Why?
|
| Prevalence | 3 | 2012 | 15732 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 1371 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 1996 | 3769 | 0.020 |
Why?
|
| Sufentanil | 1 | 2008 | 42 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 26125 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 2471 | 0.020 |
Why?
|
| Family Health | 1 | 2013 | 1257 | 0.020 |
Why?
|
| Actinin | 1 | 2009 | 163 | 0.020 |
Why?
|
| Sex Factors | 2 | 2012 | 10552 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 2009 | 163 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 1991 | 604 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2012 | 757 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 973 | 0.020 |
Why?
|
| Pentosyltransferases | 1 | 2007 | 62 | 0.020 |
Why?
|
| Analgesics | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 6310 | 0.020 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2008 | 116 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2011 | 496 | 0.020 |
Why?
|
| Germinal Center | 1 | 2010 | 380 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 2180 | 0.020 |
Why?
|
| RecQ Helicases | 1 | 2007 | 53 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1997 | 1545 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 400 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 405 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2009 | 817 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 1125 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 710 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 1060 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 1091 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 952 | 0.020 |
Why?
|
| Neuroglia | 1 | 2013 | 956 | 0.020 |
Why?
|
| Data Mining | 1 | 2012 | 551 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 387 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 2281 | 0.020 |
Why?
|
| Follow-Up Studies | 5 | 2011 | 39106 | 0.020 |
Why?
|
| Neurofilament Proteins | 1 | 2009 | 336 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1999 | 4431 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 1349 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2011 | 659 | 0.020 |
Why?
|
| Thiophenes | 1 | 1991 | 569 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 1741 | 0.020 |
Why?
|
| Viral Load | 1 | 2016 | 3332 | 0.020 |
Why?
|
| Bronchopneumonia | 1 | 2006 | 11 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 1646 | 0.020 |
Why?
|
| Models, Biological | 2 | 2001 | 9469 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3615 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2007 | 192 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 4243 | 0.020 |
Why?
|
| Anesthetics, Combined | 1 | 2006 | 43 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 1468 | 0.020 |
Why?
|
| Reoperation | 2 | 2012 | 4303 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 3510 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1996 | 2332 | 0.020 |
Why?
|
| Lymphedema | 1 | 2012 | 525 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 1486 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2007 | 419 | 0.020 |
Why?
|
| Lasers | 1 | 2010 | 952 | 0.020 |
Why?
|
| G(M1) Ganglioside | 2 | 1997 | 87 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 12441 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 21012 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2014 | 2490 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1998 | 6377 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 974 | 0.020 |
Why?
|
| Abdomen | 1 | 1991 | 1128 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 767 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 20570 | 0.020 |
Why?
|
| Analgesia, Epidural | 1 | 2008 | 332 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1347 | 0.020 |
Why?
|
| Bupivacaine | 1 | 2008 | 412 | 0.010 |
Why?
|
| Genome | 1 | 2013 | 1740 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1996 | 2882 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 3602 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 943 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 2005 | 157 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5294 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 6965 | 0.010 |
Why?
|
| RNA Interference | 1 | 2013 | 2831 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 2396 | 0.010 |
Why?
|
| North America | 1 | 2007 | 1276 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2008 | 518 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1997 | 7045 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 3429 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12059 | 0.010 |
Why?
|
| Kidney Transplantation | 2 | 2001 | 4234 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 376 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2850 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2004 | 641 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2007 | 2265 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1440 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2010 | 1742 | 0.010 |
Why?
|
| Exons | 2 | 2001 | 2391 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2010 | 1608 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2005 | 366 | 0.010 |
Why?
|
| Internationality | 1 | 2008 | 1001 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2012 | 1428 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2006 | 485 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3688 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2007 | 1967 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2557 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 427 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2007 | 1395 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 4915 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5035 | 0.010 |
Why?
|
| Peptides | 2 | 2009 | 4358 | 0.010 |
Why?
|
| Comorbidity | 2 | 2008 | 10508 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 679 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2006 | 1416 | 0.010 |
Why?
|
| Education | 1 | 2004 | 537 | 0.010 |
Why?
|
| Thrombosis | 1 | 2015 | 2942 | 0.010 |
Why?
|
| Indoles | 1 | 2009 | 1833 | 0.010 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2012 | 1533 | 0.010 |
Why?
|
| Data Collection | 1 | 2010 | 3322 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2006 | 1813 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1988 | 1378 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 1756 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 6075 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9351 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9610 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 10209 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1995 | 6567 | 0.010 |
Why?
|
| Beta Particles | 1 | 2000 | 51 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2012 | 9646 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 1993 | 3233 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 4425 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2004 | 1527 | 0.010 |
Why?
|
| Proteome | 1 | 2009 | 1862 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3600 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2000 | 8599 | 0.010 |
Why?
|
| Transfection | 2 | 1998 | 5774 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 1379 | 0.010 |
Why?
|
| Introns | 1 | 2001 | 981 | 0.010 |
Why?
|
| Causality | 1 | 2005 | 1242 | 0.010 |
Why?
|
| Isomerism | 1 | 1998 | 197 | 0.010 |
Why?
|
| Coronary Angiography | 2 | 2000 | 4471 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6484 | 0.010 |
Why?
|
| Energy Intake | 1 | 2006 | 2134 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 6425 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 14414 | 0.010 |
Why?
|
| Sample Size | 1 | 2001 | 841 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2000 | 459 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2651 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 17904 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1997 | 153 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1545 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 1971 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8547 | 0.010 |
Why?
|
| Quality of Life | 2 | 2013 | 13367 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 1998 | 242 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2001 | 1147 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2005 | 1767 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2000 | 1152 | 0.010 |
Why?
|
| Exercise | 1 | 2013 | 5890 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 16981 | 0.010 |
Why?
|
| Parathyroidectomy | 1 | 1998 | 242 | 0.010 |
Why?
|
| Goiter | 1 | 1996 | 87 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 2219 | 0.010 |
Why?
|
| Superior Cervical Ganglion | 1 | 1995 | 33 | 0.010 |
Why?
|
| Amyloid beta-Peptides | 1 | 2009 | 3839 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 2000 | 589 | 0.010 |
Why?
|
| Anus Diseases | 1 | 1996 | 55 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 885 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 1702 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 1996 | 261 | 0.010 |
Why?
|
| Ticlopidine | 1 | 2000 | 730 | 0.010 |
Why?
|
| Peripheral Nervous System | 1 | 1996 | 151 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1996 | 422 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3548 | 0.010 |
Why?
|
| Phosphorus | 1 | 1996 | 336 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 1866 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 18252 | 0.010 |
Why?
|
| Rectal Diseases | 1 | 1996 | 143 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2001 | 2257 | 0.010 |
Why?
|
| Heart Failure | 1 | 1998 | 11669 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 554 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1998 | 1463 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7407 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 4174 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 7594 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1995 | 778 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 3810 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 1999 | 2426 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1998 | 3597 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 2601 | 0.010 |
Why?
|
| Vitamin E | 1 | 1996 | 872 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 3808 | 0.010 |
Why?
|
| Carbocysteine | 1 | 1991 | 1 | 0.010 |
Why?
|
| Tiopronin | 1 | 1991 | 2 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1998 | 1803 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2001 | 1797 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1995 | 1232 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 6228 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2000 | 2188 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2135 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 2088 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 2571 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12148 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1995 | 907 | 0.010 |
Why?
|
| Lung | 1 | 2008 | 10000 | 0.010 |
Why?
|
| Walking | 1 | 1996 | 1198 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2001 | 10090 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2006 | 12953 | 0.000 |
Why?
|
| Homocysteine | 1 | 1991 | 638 | 0.000 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2000 | 2751 | 0.000 |
Why?
|
| Health Education | 1 | 1994 | 1052 | 0.000 |
Why?
|
| Genotype | 1 | 2001 | 12990 | 0.000 |
Why?
|
| Calcium | 1 | 1998 | 5722 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2007 | 23445 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1988 | 1687 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1991 | 4021 | 0.000 |
Why?
|